A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. Biomol Biomed [Internet]. 2026 Jan. 5 [cited 2026 Jan. 28];26(6):869–871. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/13832